Dienogest: A New Therapeutic Agent for the Treatment of Endometriosis
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Dienogest (DNG), a progestin of 19-nortestosterone derivative, has good oral bioavailability and is highly selective for progesterone receptors. Owing to its antiovulatory, antiproliferative activities in endometrial cells, and its inhibitory effects on the secretion of cytokines, DNG is expected to be an effective treatment for endometriosis. Progesterone receptor-binding affinity is higher for DNG than for progesterone. Several pilot studies demonstrated that after 24 weeks of DNG treatment, there was a significant decrease in terms of dysmenorrhea, premenstrual pain, dyspareunia and diffuse pelvic pain. Most of the cases of genital bleeding occurring in the DNG treatment were spotting or breakthrough bleeding, which decreased with continued treatment and resolved either during treatment or after the end of treatment. The therapeutic effects of DNG 2 mg/day and norethisterone acetate 10 mg/day for endometriotic symptoms during a period of 24 weeks were almost similar. The only disadvantage of DNG seems to be the irregular bleeding. Good efficacy and tolerability of DNG in patients with endometriosis have been demonstrated in an open, randomized European clinical trial as compared with norethisterone acetate. In Japan, a Phase III, randomized, double-blind, multicenter, controlled trial was conducted to compare the efficacy and safety of DNG with intranasal buserelin acetate in patients with endometriosis. The study demonstrated that DNG is as effective as intranasal buserelin acetate in alleviating endometriosis symptoms, and causes less bone mineral density loss, resulting in the use on a commercial basis for endometriosis patients in Japan from 2008. This paper provides summarized data on this new promising drug for endometriosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Petta, C. A., Ferriani, R. A., Abrao, M. S., Hassan, D., Rosa e Silva, J. C., Podgaec, S., & Bahamondes, L. (2005) · Human Reproduction · doi:10.1093/humrep/deh869 · Cited by 363
Olive, D. L., & Pritts, E. A. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107263450407 · Cited by 340
Vercellini, P., Frontino, G., De Giorgi, O., Aimi, G., Zaina, B., & Crosignani, P. G. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(03)00608-3 · Cited by 263
Advances in the management of endometriosis: an update for clinicians
Crosignani, P., Olive, D., Bergqvist, A., & Luciano, A. (2006) · Human Reproduction Update · doi:10.1093/humupd/dmi049 · Cited by 237
Sasagawa, S., Shimizu, Y., Kami, H., Takeuchi, T., Mita, S., Imada, K., Kato, S., & Mizuguchi, K. (2008) · Steroids · doi:10.1016/j.steroids.2007.10.003 · Cited by 177 · cited 2×
“This characteristic is attributable to its pharmacokinetic profiles and steroid hormonal specificity [15].”
BackgroundCosson, M., Querleu, D., Donnez, J., Madelenat, P., Konincks, P., Audebert, A., & Manhes, H. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(01)03270-8 · Cited by 153
Horie, S., Harada, T., Mitsunari, M., Taniguchi, F., Iwabe, T., & Terakawa, N. (2005) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.11.042 · Cited by 146
Self-citationOkada, H. (2001) · Molecular Human Reproduction · doi:10.1093/molehr/7.4.341 · Cited by 104 · cited 1×
“Owing to its antiovulatory effects in humans, antiproliferative activities in isolated human endometrial cells and its inhibitory effects on the secretion of cytokines in endometriotic stromal cells [9–11], DNG is expected to be an effective treatment for endometriosis.”
BackgroundDienogest, a synthetic steroid, suppresses both embryonic and tumor-cell-induced angiogenesis
Nakamura, M., Katsuki, Y., Shibutani, Y., & Oikawa, T. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00765-7 · Cited by 63
High-dose pilot study with the novel progestogen dienogestin patients with endometriosis
Schindler, A. E., Christensen, B., Henkel, A., Oettel, M., & Moore, C. (2006) · Gynecological Endocrinology · doi:10.1080/09513590500431482 · Cited by 53 · cited 1×
“High-dose pilot study in Europe In an open, uncontrolled study, 21 women aged 18–52 years with laparoscopically and histologically proven endometriosis (r-AFS stage I– IV) were treated with DNG 20 mg/day for 24 weeks [29].”
Method
Cited by
Progesterone resistance in endometriosis: origins, consequences and interventions
Patel, B. G., Rudnicki, M., Yu, J., Shu, Y., & Taylor, R. N. (2017) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.13156 · Cited by 336
Current and emerging treatment options for endometriosis
Ferrero, S., Evangelisti, G., & Barra, F. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1494154 · Cited by 152
Strowitzki, T., Faustmann, T., Gerlinger, C., Schumacher, U., Ahlers, C., & Seitz, C. (2015) · International Journal of Women's Health · doi:10.2147/ijwh.s77202 · Cited by 120
Barra, F., Scala, C., & Ferrero, S. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1461840 · Cited by 100
Dienogest or Norethindrone acetate for the treatment of ovarian endometriomas: Can we avoid surgery?
Del Forno, S., Mabrouk, M., Arena, A., Mattioli, G., Giaquinto, I., Paradisi, R., & Seracchioli, R. (2019) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2019.04.010 · Cited by 88
Metadata
- Authors
- Harada, T., & Taniguchi, F.
- Venue
- Women's Health
- Publisher
- SAGE Publications
- Published
- 2010-01
- Volume
- 6
- Issue
- 1
- Pages
- 27-35
- ISSN
- 1745-5057 (ISSN-L)
- 1745-5065
- OpenAlex
- W1986877495
- Cited by
- 92
- References
- 10
- FWCI
- 4.23
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dienogest: A New Therapeutic Agent for the Treatment of Endometriosis. https://app.cochat.ai/papers/10.2217/whe.09.72
- The paper
- Harada, T., & Taniguchi, F. (2010). Dienogest: A New Therapeutic Agent for the Treatment of Endometriosis. Women's Health. https://doi.org/10.2217/whe.09.72
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.